We proved that EZH2 inhibitors act as a positive regulator of TfR-1 expression by recruitment of c-Myc binding to the TfR-1 promoter, which provokes iron accumulation and facilitates DLBCL …

May 25, 2023 · By analyzing EPZ-6438 and HH2853 response profiling, we found that EZH2 inhibition increased intracellular iron through upregulation of transferrin receptor 1 (TfR-1), …

Apr 16, 2024 · Overall, EZH2's modulation of histone H3K27 me3 levels in the TFR2 promoter region affects iron homeostasis in HCC, thereby regulating ferroptosis. EZH2 is a crucial gene …

Feb 7, 2025 · Our study provides preclinical evidence supporting that EZH2 inhibitors may confer therapeutic benefit in KDM6A-deficient ESCC patients. Esophageal carcinoma (EC) is the …

Apr 18, 2018 · Ezh2, a subunit of polycomb repressive complex 2 (PRC2), maintains lower Irf4 expression. 22-23 Because of the function, Ezh2 is required for GC B cells, and a reduced …

EZH2 inhibition or SLC7A11 overexpression reverses the effects of HBx on D-GalN-induced ferroptosis. Transduced cells were treated with 50 mM D-GalN in the absence or presence of …

By analyzing the RNA-seq results, it was discovered that zeste 2 polycomb repressive complex 2 subunit (EZH2) was significantly downregulated in ferroptosis induced EESCs. Moreover, …

study reveals iron-dependent resistance evoked by EZH2i in DLBCL cells, and suggests that combination with ferroptosis inducer may be a promising therapeutic strategy.

Mar 31, 2025 · EZH2 suppression therapy reduces p-STAT3 expression, whereas EZH2 knockout decreases STAT3 and GPX4 levels. Following EZH2 suppression therapy, we aimed to …

Results show that targeted nanoparticles loading with siEZH2 synergize with Pt (IV) and result in similar cell killing performance to A2780/DDP cells (cisplatin resistant) compared with non …